

Adult Intestine Transplant Recipient Registration Worksheet

FORM APPROVED: O.M.B. NO. 0915-0157 Expiration Date: 08/31/2007

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI^B. application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI^B. application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
State of Permanent Residence: ★	
Permanent Zip: ★	-
Provider Information	
Recipient Center:	
Surgeon Name: *	
NPI:*	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
F	
Patient Status	
Primary Diagnosis:*	
Specify:	
Secondary Diagnosis:	
Specify:	
Date: Last Seen, Retransplanted or Death [★]	
Date. Last Seen, Netransplanted of Death	
	LIVING
Patient Status: *	© DEAD
	© RETRANSPLANTED
	- KETKANOI EANTED
B: 0 (B) (
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributors Course (C. d.	
Contributory Cause of Death:	

Specify:	
Transplant Hospitalization: Date of Admission to Tx Center: **	
Date of Discharge from Tx Center:	
Was patient hospitalized during the last 90 days prior to the transplant admission:	C YES NO UNK
	IN INTENSIVE CARE UNIT
Medical Condition at time of transplant: [★]	HOSPITALIZED NOT IN ICU
	NOT HOSPITALIZED
Patient on Life Support:*	G YES G NO
	☐ Ventilator
	Artificial Liver
	Other Mechanism, Specify
Specify:	
Functional Status:*	
	C No Limitations
	C Limited Mobility
Physical Capacity:	Wheelchair bound or more limited
	Not Applicable (< 1 year old or hospitalized)
	C Unknown
Working for income:	G YES G NO G UNK
If No, Not Working Due To:	
	Working Full Time
	Working Part Time due to Demands of Treatment
	Working Part Time due to Disability
	Working Part Time due to Insurance Conflict
If Yes:	Working Part Time due to Inability to Find Full Time Work
	Working Part Time due to Patient Choice
	Working Part Time Reason Unknown
	Working, Part Time vs. Full Time Unknown

	Within One Grade Level of Peers		
	Delayed Grade Level		
Academic Progress:	Special Education		
	Not Applicable < 5 years old		
	Status Unknown		
	Full academic load		
	Reduced academic load		
Academic Activity Level:	Unable to participate in academics due to disease or condition		
	Not Applicable < 5 years old/ High School graduate		
	Status Unknown		
Source of Payment:			
Primary: *			
Specify:			
Secondary:			
Clinical Information : PRETRANSPLA	AIT		
Height: *	ftincm %ile ST=		
Weight: *	lbs kg %ile ST=		
BMI:	kg/m ² %ile		
Previous Transplants:			
Previous Transplant Organ	Previous Transplant Date Previous Transplant Graft Fail Date		
The three most recent transplants are listed	here. Please contact the UNet Help Desk to confirm more than three previous transplants by calling 80		
978-4334 or by emailing unethelpdesk@un	os.org.		
Viral Detection:			
	© Positive		
	Negative		
HIV Serostatus: ≭	C Not Done		
	UNK/Cannot Disclose		
	Positive		
	Negative		
CMV IgG: ≭	Not Done		
	UNK/Cannot Disclose		

CMV IoM·*	C Positive				
	Negative				
CMV IgM:*	Not Done				
	C UNK/Cannot Disclose				
HBV Core Antibody: ▼	C Positive				
	Negative				
TIBV Core Antibody.**	Not Done				
	C UNK/Cannot Disclose				
	C Positive				
HBV Surface Antigen: ▼	Negative				
	Not Done				
	C UNK/Cannot Disclose				
HCV Serostatus: ≭	O Positive				
	Negative				
	Not Done				
	C UNK/Cannot Disclose				
	C Positive				
EBV Serostatus: ≭	Negative				
	Not Done				
	C UNK/Cannot Disclose				
Total Bilirubin: *	mg/dl ST=				
Serum Albumin:*	g/dl ST=				
Serum Creatinine: ★	mg/dl ST=				
Malignancies between listing and transplant:*	C YES NO UNK				
This question is NOT applicable for patients receiving living of	lonor transplants who were never on the waiting list.				
	Skin Melanoma				
	Skin Non-Melanoma				
If you appoin type:	CNS Tumor				
If yes, specify type:	Genitourinary Genitourinary				
	□ Breast				
	☐ Thyroid				

	☐ Tongue/Throat/Larynx					
	Lung					
	Leukemia/Lymphoma					
	Liver					
	Other, specify					
Specify:						
-13						
Clinical Information : TRANSPLANT PROCEDURE						
Multiple Organ Recipient						
Were extra vessels used in the transplant procedure:						
Procedure Information:						
Intestine Only Venous Drainage:*	Portal Systemic					
Native Viscera Venous Drainage:∗	Portal Systemic					
	Whole Intestine					
	C Intestine Segment					
Procedure Type:	Whole Intestine with Pancreas (Technical Reasons)					
	Intestine Segment with Pancreas (Technical Reasons)					
Organ Type: ★	☐ Stomach					
	Small Intestine					
	Duodenum					
	☐ Large Intestine					
Preservation Information:						
Total Ischemic Time (include cold, warm and anastomotic time): ★	hrs ST=					
Risk Factors:						
Recent Septicemia: *	C YES O NO UNK					
Exhausted Vascular Access:*	C YES O NO UNK					
Liver Dysfunction:	G YES G NO G UNK					
Previous Abdominal Surgery:*	C YES ONO UNK					
Number Previous Abdominal Surgeries:	ST=					
Dilated/Non-Functional Bowel Segments: *	C YES C NO C UNK					

Other:						
Clinical Information : POST TRANSPLANT						
Graft Status:*	Functioning Failed					
If death is indicated for the recipient, and the death was a res	sult of some other factor unrelated to graft failure, select Functioning.					
TPN Dependent:	C YES NO					
IV Dependent:	C YES NO					
Oral Feeding:	C YES C NO					
Tube Feed:	C YES NO					
Date of Graft Failure:						
	© RECURRENT TUMOR					
	ACUTE REJECTION					
Primary Cause of Graft Failure:	CHRONIC REJECTION					
	TECHNICAL PROBLEMS					
	© INFECTION					
	LYMPHOPROLIFERATIVE DISEASE					
	OTHER SPECIFY					
Specify:						
	Yes, at least one episode treated with anti-rejection agent					
Did patient have any acute rejection episodes between transplant and discharge: ★	Yes, none treated with additional anti-rejection agent					
	No No					
	Biopsy not done					
Was biopsy done to confirm acute rejection:	Yes, rejection confirmed					
	 Yes, rejection not confirmed 					
Treatment						
Biological or Anti-viral Therapy:	C YES NO Unknown/Cannot disclose					
	Acyclovir (Zovirax)					
	Cytogam (CMV)					
	☐ Gamimune					

☐ Gammagard

	Ganciclovir (Cytovene)				
	☐ Valgancyclovir (Valcyte)				
	HBIG (Hepatitis B Immune Globulin)				
If Yes, check all that apply:	Flu Vaccine (Influenza Virus)				
	Lamivudine (Epivir) (for treatment of Hepatitis B)				
	Other, Specify				
	Valacyclovir (Valtrex)				
Specify:					
Specify:					
Other therapies:	C YES C NO				
	Photopheresis				
If Yes, check all that apply:	Plasmapheresis				
	☐ Total Lymphoid Irradiation (TLI)				
Immunosuppressive Information					
Are any medications given currently for maintenance or anti-rejection: *	C YES NO				
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES C NO				
If Yes, Specify:					
Immunosuppressive Medications					
View Immunosuppressive Medications					
Definitions Of Immunosuppressive Medications					

For each of the immunosuppressive medications listed, select **Ind** (Induction), **Maint** (Maintenance) or **AR** (Anti-rejection) to indicate all medications that were prescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank.

Induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection. Though the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: Methylprednisolone, Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some of these drugs might be used for another finite period for rejection therapy and would be recorded as rejection therapy if used for this reason. For each induction medication indicated, write the total number of days the drug was actually administered in the space provided. For example, if Simulect or Zenapax was given in 2 doses a week apart, then the total number of days would be 2, even if the second dose was given after the patient was discharged.

Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes, or for induction.

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial post-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive**

medications.				
	Ind.	Days	ST	
Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadron)				
Atgam (ATG)				
OKT3 (Orthoclone, Muromonab)				
Thymoglobulin				
Simulect - Basiliximab				
Zenapax - Daclizumab				
Azathioprine (AZA, Imuran)	п			
EON (Generic Cyclosporine)	п			
Gengraf (Abbott Cyclosporine)	п			
Other generic Cyclosporine, specify brand:				
Neoral (CyA-NOF)	п			
Sandimmune (Cyclosporine A)	П			
Mycophenolate Mofetil (MMF, Cellcept, RS61443)	п			
Tacrolimus (Prograf, FK506)				
Modified Release Tacrolimus FK506E (MR4)				
Sirolimus (RAPA, Rapamycin, Rapamune)				
Myfortic (Mycophenolate Sodium)	_			
Other Immunosuppressive Medications	Ind. Days		от ВТ	Maint AR
Campath - Alemtuzumab (anti-CD52)	ind. Days		, i	
Cyclophosphamide (Cytoxan)				
			I	

Leflunomide (LFL, Arava)	Г				
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)					
Other Immunosuppressive Medication, Specify					
Other Immunosuppressive Medication, Specify					
Rituximab					
Investigational Immunosuppressive Medications					
	Ind.	Days	ST	Maint	AR
Everolimus (RAD, Certican)					
FTY 720					
UNOS View Only					[
Comments:					